News
Upperton applies for rP-conjugate™ Trademark
NOTTINGHAM, UK – February 24, 2012 – Upperton is pleased to announce that it has received a trademark for its novel conjugation technology platform.
Conjugating Recombumin® Flex to drugs offers the opportunity to dramatically enhance patient lives and drive down healthcare costs.
NOTTINGHAM, UK – December 8, 2011 – Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, has announced that it has expanded its partnership with Nottingham-based research and development company, Upperton Limited, to offer customers a new albumin conjugation solution. By linking drugs to Novozymes' new Recombumin® Flex recombinant human albumin (rAlbumin), using conjugation, their pharmacokinetic and pharmacodynamic properties can be dramatically enhanced. As a result, manufacturers can benefit from the ability to tailor and control the half-life of drugs to fit patients' medical needs.
Print